Total Payments
$5,691
2024 Payments
$794.62
Companies
46
Transactions
377
Medicare Patients
623
Medicare Billing
$33,497
Payment Breakdown by Category
Food & Beverage$5,677 (99.8%)
Education$13.89 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,677 | 376 | 99.8% |
| Education | $13.89 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $768.70 | 47 | $0 (2024) |
| Novo Nordisk Inc | $657.05 | 45 | $0 (2024) |
| Lilly USA, LLC | $551.75 | 39 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $518.98 | 29 | $0 (2024) |
| Amgen Inc. | $436.79 | 26 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $180.79 | 13 | $0 (2020) |
| Allergan, Inc. | $171.80 | 9 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $171.14 | 12 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $170.61 | 11 | $0 (2022) |
| Biohaven Pharmaceutical Holding Company Ltd. | $164.61 | 16 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $794.62 | 46 | Novo Nordisk Inc ($174.53) |
| 2023 | $841.41 | 50 | Otsuka America Pharmaceutical, Inc. ($216.61) |
| 2022 | $1,552 | 108 | ABBVIE INC. ($335.73) |
| 2021 | $570.26 | 39 | AbbVie Inc. ($218.20) |
| 2020 | $314.35 | 20 | Allergan, Inc. ($83.72) |
| 2019 | $890.03 | 66 | Sunovion Pharmaceuticals Inc. ($151.87) |
| 2018 | $350.82 | 25 | Novo Nordisk Inc ($59.84) |
| 2017 | $377.11 | 23 | Amgen Inc. ($115.32) |
All Payment Transactions
377 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: PSYCHIATRY | ||||||
| 11/27/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $7.33 | General |
| Category: Diabetes | ||||||
| 11/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $3.28 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Diabetes Care | ||||||
| 10/16/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Biological | ||||||
| 09/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.73 | General |
| Category: Diabetes | ||||||
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.78 | General |
| 08/29/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Diabetes | ||||||
| 08/28/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Diabetes | ||||||
| 08/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: VACCINE | ||||||
| 08/01/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Biological | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.65 | General |
| 07/31/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Diabetes | ||||||
| 07/26/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Inflammation | ||||||
| 07/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Bone Health | ||||||
| 07/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Diabetes | ||||||
| 06/24/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 195 | 240 | $24,679 | $8,937 |
| 2022 | 5 | 104 | 135 | $14,354 | $5,070 |
| 2021 | 6 | 148 | 213 | $26,041 | $8,744 |
| 2020 | 6 | 176 | 236 | $31,061 | $10,746 |
Total Patients
623
Total Services
824
Medicare Billing
$33,497
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 37 | 39 | $5,704 | $2,344 | 41.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 29 | 61 | $5,152 | $2,125 | 41.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $4,598 | $1,742 | 37.9% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 24 | 24 | $4,005 | $1,443 | 36.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 14 | $1,759 | $770.02 | 43.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 63 | 69 | $2,843 | $420.90 | 14.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 13 | 15 | $618.00 | $91.50 | 14.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 27 | 29 | $4,839 | $2,054 | 42.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 32 | 56 | $4,730 | $1,530 | 32.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 23 | 26 | $3,803 | $1,323 | 34.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 11 | 11 | $428.34 | $86.90 | 20.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 11 | 13 | $553.80 | $75.27 | 13.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 37 | 86 | $7,264 | $2,492 | 34.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 43 | 46 | $6,728 | $2,373 | 35.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 22 | 23 | $3,838 | $1,594 | 41.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 22 | $2,960 | $1,202 | 40.6% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 11 | 11 | $4,185 | $929.55 | 22.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 22 | 25 | $1,066 | $153.36 | 14.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 50 | 58 | $8,794 | $3,202 | 36.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 49 | 95 | $8,131 | $2,880 | 35.4% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 28 | 28 | $5,099 | $2,186 | 42.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 19 | 24 | $4,092 | $1,317 | 32.2% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 14 | 15 | $2,854 | $705.52 | 24.7% |
| 99282 | Emergency department visit, low to moderately severe problem | Facility | 2020 | 16 | 16 | $2,090 | $454.97 | 21.8% |
About Dr. Christopher Jarvis, M.D
Dr. Christopher Jarvis, M.D is a Family Medicine healthcare provider based in Burlington, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1508860479.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Jarvis, M.D has received a total of $5,691 in payments from pharmaceutical and medical device companies, with $794.62 received in 2024. These payments were reported across 377 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($5,677).
As a Medicare-enrolled provider, Jarvis has provided services to 623 Medicare beneficiaries, totaling 824 services with total Medicare billing of $33,497. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Burlington, KS
- Active Since 06/09/2005
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1508860479
Products in Payments
- VRAYLAR (Drug) $426.31
- REXULTI (Drug) $421.16
- Ozempic (Drug) $339.98
- UBRELVY (Drug) $338.39
- MOUNJARO (Drug) $278.11
- NURTEC ODT (Drug) $182.16
- Rybelsus (Drug) $174.93
- TRULICITY (Drug) $157.12
- EVENITY (Biological) $151.98
- LONHALA MAGNAIR (Drug) $151.87
- ELIQUIS (Drug) $138.38
- ABILIFY MAINTENA (Drug) $135.31
- XARELTO (Drug) $121.47
- FREESTYLE LIBRE 2 (Device) $117.54
- QULIPTA (Drug) $116.92
- Prolia (Biological) $108.08
- Prolastin-C Liquid (Biological) $98.32
- TROKENDI XR (Drug) $93.63
- XIFAXAN (Drug) $90.91
- BELSOMRA (Drug) $88.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Burlington
Krichna Sowles, Md, MD
Family Medicine — Payments: $17,218
Family Medicine $17,218
Dr. Jasmine Bajaj, Md, MD
Family Medicine — Payments: $8,590
Family Medicine $8,590
Dr. Richard Gilbert, Md, MD
Family Medicine — Payments: $7,905
Family Medicine $7,905
Michol Negron, D.o, D.O
Family Medicine — Payments: $7,588
Family Medicine $7,588
Dr. Donald Fisher, Md, MD
Family Medicine — Payments: $7,370
Family Medicine $7,370
Jeff Sloyer, M.d, M.D
Family Medicine — Payments: $5,178
Family Medicine $5,178